Compare MTRX & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTRX | AUTL |
|---|---|---|
| Founded | 1984 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.7M | 407.2M |
| IPO Year | 1995 | 2025 |
| Metric | MTRX | AUTL |
|---|---|---|
| Price | $13.16 | $1.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.00 | $8.50 |
| AVG Volume (30 Days) | 272.9K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $769,286,000.00 | $10,120,000.00 |
| Revenue This Year | $19.75 | $80.32 |
| Revenue Next Year | $7.96 | $53.96 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 5.64 | ★ 496.00 |
| 52 Week Low | $9.88 | $1.18 |
| 52 Week High | $16.11 | $2.70 |
| Indicator | MTRX | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 57.94 | 64.77 |
| Support Level | $11.93 | $1.27 |
| Resistance Level | $13.44 | $1.98 |
| Average True Range (ATR) | 0.45 | 0.13 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 89.59 | 86.54 |
Matrix Service Co provides engineering, fabrication, construction, maintenance, and repair services prominently to the energy and industrial markets. The company operates through three main segments: Storage and Terminal Solutions, Utility and Power Infrastructure, and Process and Industrial Facilities. These segments cover services like building and maintaining storage tanks and terminals, supporting power delivery and new power generation projects including renewables, as well as plant maintenance and turnarounds for refining and petrochemical industries. Matrix generates revenue by delivering these services to clients in oil, gas, power, and petrochemical sectors across North America and internationally.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.